National Bank of Canada FI Has $30.19 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

National Bank of Canada FI raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 17.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 73,028 shares of the company's stock after purchasing an additional 10,592 shares during the quarter. National Bank of Canada FI owned about 0.09% of IDEXX Laboratories worth $30,193,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Insight Wealth Strategies LLC raised its holdings in shares of IDEXX Laboratories by 230.5% during the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock valued at $4,174,000 after acquiring an additional 7,041 shares during the period. Geode Capital Management LLC raised its position in IDEXX Laboratories by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company's stock worth $1,138,732,000 after purchasing an additional 40,349 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $1,263,000. Sax Wealth Advisors LLC increased its stake in shares of IDEXX Laboratories by 76.3% in the 4th quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company's stock valued at $590,000 after buying an additional 617 shares during the period. Finally, Hantz Financial Services Inc. grew its holdings in IDEXX Laboratories by 11.5% during the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company's stock worth $3,199,000 after acquiring an additional 800 shares during the period. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Price Performance

NASDAQ IDXX traded down $10.99 during trading hours on Monday, reaching $382.74. The company's stock had a trading volume of 803,613 shares, compared to its average volume of 736,816. The company's 50-day moving average is $435.55 and its two-hundred day moving average is $439.31. IDEXX Laboratories, Inc. has a fifty-two week low of $366.50 and a fifty-two week high of $548.88. The stock has a market cap of $31.02 billion, a PE ratio of 35.63, a PEG ratio of 3.41 and a beta of 1.50. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company's stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on IDXX. Piper Sandler increased their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Friday. Morgan Stanley cut their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Finally, Barclays lifted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and a consensus price target of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.